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a  b  s  t r  a  c  t
TNF-related  apoptosis  inducing  ligand  (TRAIL)  selectively  induces  apoptosis  in cancer  cells  without  harm-
ing  most  normal  cells.  Currently,  multiple  clinical  trials  are  underway  to evaluate  the  antitumor  activity
of  recombinant  human  TRAIL  (rhTRAIL)  and  agonistic  antibodies  that target  death  receptors  (DRs)  4 or  5.
It  is  encouraging  that these  products  have  shown  a tolerated  safety  proﬁle  in  early  phase  studies.  How-
ever,  their  therapeutic  potential  is likely  limited  by the emergence  of  tumor  drug  resistance  phenomena.
Increasing  evidence  indicates  that  TRAIL  DRs  are  deﬁcient  on the plasma  membrane  of some  cancer
cells  despite  their  total  protein  expression.  Notably,  the  lack  of  surface  DR4/DR5  is  sufﬁcient  to  ren-
der  cancers  resistant  to TRAIL-induced  apoptosis,  regardless  of  the  status  of other  apoptosis  signalingargeted cancer therapy
rug resistance
components.  The  current  review  highlights  recent  ﬁndings  on  the  dynamic  expression  of  TRAIL  death
receptors,  including  the  regulatory  roles  of  endocytosis,  autophagy,  and  Ras GTPase-mediated  signaling
events.  This  information  could  aid  in the identiﬁcation  of novel  predictive  biomarkers  of  tumor  response
as well  as  the  development  of  combinational  drugs  to  overcome  or bypass  tumor  drug  resistance  to  TRAIL
receptor-targeted  therapies.
Published  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ontents
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. Introduction
Drug resistance is a major cause of cancer treatment failure
nd it is closely related to the inherent heterogeneity of tumor
ells as being found between tumor types, individuals with the
ame type of tumor, and within one tumor of a patient at any
 The views presented in this article are based on our own research ﬁndings and
 survey of the related scientiﬁc publications, and they do not necessarily reﬂect
given time. Therefore, the ability to identify or stratify the sub-
sets of patients with molecularly deﬁned cancers could signiﬁcantly
improve patient outcome. Numerous strategies are being explored
to overcome intrinsic and acquired drug resistance mechanisms;
for examples, targeting the ATP-driven efﬂux transporters (Choi
and Yu, 2014; Goler-Baron and Assaraf, 2012; Shapira et al., 2011),
upregulation of proteases (de Wilt et al., 2012; Fall et al., 2014;
Niewerth et al., 2014a,b,c; Orlowski, 2013), and lysosomal drug-
sequestration (Adar et al., 2012; Zhitomirsky and Assaraf, 2015).
Death receptors (DRs), including TNF receptor 1 (TNFR1), Fas,
hose of the Food and Drug Administration (FDA).
∗ Corresponding author at: Food and Drug Administration, 10903 New Hampshire
venue, Building 52, Room 2128, Silver Spring, MD 20993, United States.
el.: +1 240 402 6740.
E-mail address: Baolin.Zhang@fda.hhs.gov (B. Zhang).
ttp://dx.doi.org/10.1016/j.drup.2015.02.001
368-7646/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-NDR4 and DR5, are attractive targets for cancer therapy. These DRs
are characterized by an intracellular death domain which transmits
a death signal from their cognate ligands such as TNF-, Fas ligand
(FasL), or TNF-related apoptosis-inducing ligand (TRAIL). Compared
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Current clinical trials involving rhTRAIL and DR4/5 agonistic antibodies.a
Drug Name Combined with: Phase Tumor Type Study Years Enrolled
Patients
Sponsor Clin. Trial ID
Apo2L/ rhTRAIL Dulanermin Arm 1: Cetuximab + Irinotecan + Dulanermin
Arm 2: Bevacizumab + FOLFIRI + Dulanermin
Ib Colorectal Cancer 2006–2012 42 Genetech NCT00671372
Dulanermin Arm 1: Dulanermin + Bevacizumab + FOLFOX I Metastatic Colorectal
Cancer
2009–2014 23 Genetech NCT00873756
AMG  951 Arm 1: Carboplatin + Paclitaxel + Bevacizumab
Arm 2: Carboplatin + Paclitaxel + Bevacizumab + AMG 951
Arm 3: Carboplatin + Paclitaxel
Arm 4: Carboplatin + Bevacuzimab + AMG 651
II NSCLCb 2007–2012 213 Amgen NCT00508625
Anti-DR4 Mapatumumab Arm 1: Mapatumumab + Sorafenib I Hepatocellular
Carcinoma
2008–2012 23 GSK NCT00712855
Mapatumumab Arm 1: Mapatumumab +Sorafenib
Arm 2: Placebo + Sorafenib
II Hepatocellular
Carcinoma
2011–2014 101 GSK Clinical Trials NCT01258608
Mapatumumab Arm 1: Paclitaxel + Carboplatin
Arm 2: Carboplatin + Mapatumumab
Arm 3: Paclitaxel + Carboplatin + Mapatumumab
II NSCLC 2007–2011 111 GSK Clinical Trials NCT00583830
Mapatumumab Arm 1: Mapatumumab + Cisplatin + Radiotherapy Ib/II Cervical Cancer 2010–2014 9 NCT01088347
Mapatumumab Arm 1: Bortezomib
Arm 2: Bortezomib + Mapatumumab (low dose)
Arm 3: Bortezomib + Mapatumumab (high dose)
II Multiple Myeloma 2006–2010 105 GSK NCT00315757
TRM-1 Arm 1: TRM-1 II NSCLC 2005 n/a GSK NCT00092924
TRM-1 Arm 1: TRM-1 II Non-Hodgkin’s
Lymphoma
2004–2007 n/a GSK NCT00094848
Anti-DR5 Conatumumab Arm 1: AMG 655 (high dose) + paclitaxel/carboplatin
Arm 2: AMG 655 (low dose) + paclitaxel/carboplatin
Arm 3: Placebo + paclitaxel/ carboplatin
Ib/II NSCLC 2008–2011 172 Amgen NCT00534027
Conatumumab Arm 1: AMG 655 (low dose) + mFOLFOX6 + Bevacizumab
Arm 2: AMG 655 (high dose) + mFOLFOX6 + Bevacizumab
Arm 3: Placebo + mFOLFOX6 + Bevacizumab
Ib/II Metastatic Colon
Cancer
2007–2011 202 NCT00625651
Conatumumab Arm 1: AMG 655 + Doxorubicin
Arm 2: Placebo + Doxorubicin
Ib/II Soft Tissue Sarcoma 2007–2011 134 Amgen NCT00626704
Conatumumab Arm 1: Placebo + Gemcitabine Ib/II Metastatic Pancreatic
Cancer
2007–2012 138 Amgen NCT00630552
Arm  2: AMG 655 + Gemcitabine
Arm 3: AMG 479 + Gemcitabine
Conatumumab Arm 1: FOLFIRI + AMG  655 + Placebo
Arm 2: FOLFIRI + AMG  479 + Placebo
Arm 3: FOLFIRI + AMG  655 + AMG  479
II Metastatic Colorectal
Cancer
2009–2012 155 Amgen NCT00813605
Conatumumab Arm 1: AMG 655 (intermediate dose) + Vorinostat
Arm 2: AMG 655 (low dose) + Bortezomib
Arm 3: AMG 655 (low dose) + Vorinostat
Arm 4: AMG 655(high dose) + Bortezomib
Arm 5: AMG 655 (high dose) + Vorinostat
Arm 6: AMG 655 (TBD dose) + Bortezomib
Arm 7: AMG 655 (intermediate dose) + Bortezomib
Ib Lymphoma 2008–2011 33 Amgen NCT00791011
Conatumumab Arm 1: AMG 655 + Panitumumab Ib/II Metastatic Colon
Cancer
53 Amgen NCT00630786
CS-1008 Arm 1: CS-1008 + Gemcitabine II Pancreatic Cancer 2007–2008 65 Daiichi Sankyo Inc. NCT00521404
Lexatumumab Arm 1: HGS-ETR2
Arm 2: HGS-ETR2 + recombinant interfereon gamma
I Metastatic Tumors 2006–2011 19 NCT00428272
J.D. Twomey et al. / Drug Resistanc
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to TNF-, which is known to elicit severe toxicity after systemic
exposure, TRAIL appears to selectively induce apoptosis in cancer
cells without harming most normal cells and healthy tissues (Castro
et al., 2012; Lawrence et al., 2001; Oikonomou et al., 2007; Walczak
et al., 1999). This unique selectivity has prompted multiple clini-
cal trials to evaluate the antitumor activity of recombinant human
TRAIL (rhTRAIL) and its receptor agonistic antibodies (Table 1). It
is encouraging that these products have shown a tolerated safety
proﬁle in early phase clinical studies (Daniel and Wilson, 2008;
Herbst et al., 2010; Leong et al., 2009; Roberts et al., 2011). How-
ever, their therapeutic potential is likely limited by the emergence
of various drug resistance phenomena that has been seen in a large
number of human cancer cell lines and primary tumors. There is an
unmet need of biomarkers that can help identify patient subpop-
ulations that are likely responsive or drug resistant to the speciﬁc
treatments. To achieve better treatment outcomes, ongoing phase
2 clinical trials are focused on the evaluation of TRAIL receptor
agonists in combination with various chemotherapies or targeted
therapies (Soria et al., 2011; Thorburn et al., 2008).
TRAIL induces apoptosis through engaging DR4 and/or DR5
expressed on the plasma membrane of target cancer cells. The
sequential signaling events involve the assembly of a death induc-
ing signaling complex (DISC), activation of a caspase cascade,
cleavage of cellular proteins, and eventually the execution of apo-
ptosis (Fig. 1) (Aza-Blanc et al., 2003; Kischkel et al., 2000, 2001).
Although TRAIL elicits cytotoxic effects in some malignant cells,
those with highly malignant tumors such as pancreatic cancer (Hinz
et al., 2000), malignant melanoma (Fulda et al., 2001), neuroblas-
toma (Eggert et al., 2001), and breast cancer (Keane et al., 1999;
Singh et al., 2003; Zhang and Zhang, 2008; Zhao et al., 2007), are
resistant to TRAIL-induced apoptosis (Ozoren and El-Deiry, 2003).
A variety of cellular factors have been associated with TRAIL resis-
tance, which are described in several excellent reviews (Crowder
and El-Deiry, 2012; Dimberg et al., 2013; Fulda, 2015; Held and
Schulze-Osthoff, 2001; Mellier and Pervaiz, 2012; Shankar and
Srivastava, 2004; Siegelin, 2012; Stegehuis et al., 2010; Thorburn
et al., 2008; van Geelen et al., 2004; van Roosmalen et al., 2014).
These cellular factors include defects in TRAIL signaling com-
ponents (e.g. deﬁciency of caspase 8 and elevated expression of
FLIP) as well as the deregulated expression of apoptosis regulatory
proteins (e.g. Bcl2 and cIAP family proteins). Recent studies demon-
strate a close association between TRAIL resistance and defects in
TRAIL receptors themselves. Moreover, increasing evidence shows
that DR4 and DR5 are functionally defective in different types of
cancer cells (Snow et al., 2006). Despite their protein expression,
DR4 and/or DR5 are found to be absent on the surface of these
malignant cells. Notably, lack of surface DR4 and DR5 appears to
be sufﬁcient to render tumors resistance to the targeted thera-
pies regardless of the expression levels of other relevant signaling
molecules. This review provides an update of the current knowl-
edge on TRAIL resistance, highlighting the mechanisms responsible
for the functional deﬁciency of TRAIL receptors in cancer cells.
2. Regulation of TRAIL DRs
2.1. Transcriptional regulation of DR4 and DR5
The signaling pathway illustrated in Fig. 1 suggests that TRAIL-
induced apoptosis is independent of p53 activity. Because p53 is
mutated in about 50% of human tumors, which confers upon tumors
drug resistance to classical DNA-damaging agents, it was  initially
thought that DR4 and DR5 agonists could be used to kill cancer
cells expressing mutant p53. However, this idea is now challenged
by the fact that p53 is a transcriptional regulatory factor of the DR5
gene (Takimoto and El-Deiry, 2000; Wu  et al., 1997). Consistently,
16 J.D. Twomey et al. / Drug Resistance Updates 19 (2015) 13–21
Fig. 1. Dynamic expression of TRAIL death receptors. In the TRAIL-induced apoptosis pathway, TRAIL ligation of DR4/5 causes assembly of the death induced signaling
complex (DISC) composed of Fas-associated death domain (FADD) and pro-caspase 8/10 (Pro-C8/10) which then is processed and released into cytoplasm to initiate effector
caspase (C3/7) mediated apoptosis. Activated caspase-8 can also cause the cleavage of Bid into tBid, linking to mitochondrial-dependent activation of the caspase cascade.
Resistance to TRAIL-mediated apoptosis can be caused by surface deﬁciency of the death receptors through deregulation of both transcriptional and post-translational
pathways. Transcriptional regulation of the death receptors is through transcription factors which either cause upregulation of the DRs (black) or inhibit DR transcription
(red)  (*DR4 speciﬁc; **DR5 speciﬁc). Several chemotherapies have been implicated in modulating this transcriptional regulation. Post-translational modiﬁcations of the DRs
(e.g.  glycosylation) within the endoplasmic reticulum (ER) and trans-Golgi network (TGN) are required for the translocation of the receptors to the plasma membrane. In some
cancer  cells however, DRs may  be trapped within autophagosomes, the nucleus and/or nuclear membrane, or remain within the ER/TGN, resulting in cell surface deﬁciency.
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tross-talk with the EGFR/Ras signaling pathways through upregulated H-Ras could r
trengthening the tumor cell’s resistance to TRAIL-induced apoptosis. To overcome 
resentation of DRs through harnessing alternate pathways in combination with rh
ome chemotherapeutic agents can increase TRAIL induced apo-
tosis through upregulation of DR5 gene expression in cancer cells
xpressing functional p53 (Mahalingam et al., 2009). We  speculate
hat p53 mutation status may  be related to the expression levels of
R5 and that may  be a determinant of cellular sensitivity to TRAIL
nduced apoptosis.
DR5 gene expression is regulated by stress-induced transcrip-
ion factors including CHOP, Elk1, NF-B, AP-1, Sp1, FOXO3a, andin increased endocytosis and/or increased autophagosomal localization, potentially
resistance mechanisms, therapeutics should aim to enhance or stabilize the surface
 and DR4/5 agonistic antibodies.
Ying Yang 1 (YY1) (Sheikh et al., 1998; Yoshida et al., 2001).
For example, CHOP modulates DR5 mRNA expression through
the binding region in the 5′-ﬂanking region of the DR5 gene
(Yamaguchi and Wang, 2004). Elk1 cooperates with CHOP in the
regulation of DR5 gene expression (Oh et al., 2010). NF-B is also
known to be a key transcriptional regulator of DR5 gene expres-
sion (Chen et al., 2003; Ravi et al., 2001; Shetty et al., 2002,
2005).
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The promoter of the DR5 gene contains several functional
egions for the binding of transacting factors including AP-1 and
p1 (Moon et al., 2012). AP-1, a dimeric complex composed of
-Jun and c-Fos, has been shown to upregulate DR5 gene expres-
ion in response to JNK activation (Zou et al., 2004). Four putative
p1-binding regions were found in the DR5 promoter, which were
hown to upregulate DR5 gene expression in cells treated with cyto-
oxic drugs. The AKT downstream transcription factor FOXO3a was
hown to be involved in the transcriptional regulation of DR4 and
R5 genes (Chen et al., 2010; Ganapathy et al., 2010). There is also
vidence that the YY1 protein acts as a transcriptional repressor of
R5. YY1 is a ubiquitously expressed zinc ﬁnger factor that coop-
rates with other transcription factors to act as either an activator
r transcriptional repressor of its target genes. Blockage of NF-B
ignal caused inhibition of YY1, resulting in upregulation of DR5
Baritaki et al., 2007a,b, 2008). Additionally, histone deacetylase
nhibitors also cause upregulation of DR4 and DR5 mRNA levels as
ell as protein levels (Singh et al., 2005). These inhibitors function
o block histone deacetylation and facilitate transcription through
he above mentioned transcription factors such as Sp1 or NF-B
Singh et al., 2005).
DR4 gene expression shares several transcription factors with
hat of DR5 such as p53, NF-B, CHOP, FOXO3a, and AP-1 (Guan
t al., 2001, 2002; Jin et al., 2014; Mendoza et al., 2008; Ravi et al.,
001; Shoeb et al., 2013). However, GLI-3 was suggested to be the
nique transcription repressor of DR4 gene expression (Kurita et al.,
010). In principle, therapeutic agents that can upregulate DR4/DR5
ene expression may  have a potential to increase cellular sensi-
ivity to apoptosis induction by rhTRAIL or DR4/5 antibodies. A
ynergistic effect was shown when combining with thapsigargin
Yamaguchi and Wang, 2004) and proteasome inhibitor MG132
Yoshida et al., 2005), both of which upregulate CHOP protein
xpression, capsaicin increases Sp1 expression (Moon et al., 2012),
r NPI-0052 represses YY1 expression (Baritaki et al., 2008). As
esearch on the transcriptional regulation of the DR4 and DR5 genes
dvances, the cumulative information can help the selection of drug
ombinations that can enhance the therapeutic activity of TRAIL
eceptor targeted therapies.
.2. Post-translational modiﬁcations of TRAIL DRs
Although DR4 and DR5 gene expression is found in a wide
pectrum of tumor cells including breast cancer cells, there is no
orrelative link between total receptor protein expression lev-
ls and the sensitivity of tumors to rhTRAIL. Increasing evidence
emonstrates that the mRNA expression of TRAIL receptors does
ot necessarily reﬂect their functional protein expression due to
he complex post-translational modiﬁcations of the synthesized
eceptor proteins. These include protein glycosylation, trafﬁcking,
nd endocytosis processes. Here we survey the recent ﬁndings
n the relevant areas, as well as the emerging regulatory roles of
utophagy and Ras GTPase-mediated signaling events.
Glycosylation of TRAIL receptors. Glycosylation of proteins is a
omplex post-translational modiﬁcation that attaches glycans at
peciﬁc sites on a protein, most commonly at Asn (N-linked) or
er/Thr (O-linked) residues. DR4 and DR5 have been shown to
ndergo N- or O-linked glycosylation in a cell type dependent
anner, thereby modulating their cellular sensitivity to TRAIL
Jin et al., 2004; Wagner et al., 2007). O-linked glycosylation of
R5 is catalyzed by N-acetyl-galactosamine (GalNAc) transferase
GALNT) 3, GALNT14, and -(1,3)-fucosyltransferase (FUT), trans-
erring GalNAc to serine and threonine residues in the polypeptide
xtracellular domain (Wagner et al., 2007). O-glycosylation is sug-
ested to increase membrane stability of the receptors, preventing
ndocytosis (Wu  et al., 2012), and facilitating receptor translo-
ation into clusters for DISC assembly and caspase-8 activatione Updates 19 (2015) 13–21 17
(Wagner et al., 2007; Wu  et al., 2012). Increased levels of the
glycosylated proteins directly correlate with TRAIL sensitivity in
colorectal, pancreatic, non-small cell lung cancer (NSCLC), and
melanoma cell lines (Wagner et al., 2007). Consistently, the vast
majority of TRAIL-sensitive tumor cell lines expressed higher levels
of peptidyl O-glycosyltransferase (Wagner et al., 2007). Knock-
down of GALNT14 inhibited DISC recruitment, through reduced
translocation of DR4 and DR5, but also by surface deﬁciency of the
receptors (Wagner et al., 2007). N-linked glycosylation of DR4 was
shown to stabilize the receptor on the plasma membrane (Yoshida
et al., 2007).
Glycosylated receptors can be bound by galectins on the plasma
membrane, which will inhibit DR internalization (Mazurek et al.,
2012). The geometry of galectin-3 allows for different glycoproteins
to participate in higher order lattice structures (Ahmad et al., 2004),
thereby stabilizing the DRs and epidermal growth factor receptor
(EGFR) on the membrane (Partridge et al., 2004).
Trafﬁcking to plasma membrane. Surface expression of DRs is
dependent on translocation of the protein from the trans-Golgi net-
work (TGN) to the plasma membrane. This sorting to the plasma
membrane is regulated by cargo transport proteins such as Arf and
Rho GAP protein ARAP1 (Simova et al., 2008) and nuclear translo-
cation signaling proteins (Kojima et al., 2011). Malfunctions in this
pathway will result in surface deﬁciency of DRs and an increase in
localization to the cytosol (Kojima et al., 2011), the TGN (Simova
et al., 2008; Zhang et al., 2000) and nuclear perimeter (Jin et al.,
2004; Kojima et al., 2011; Leithner et al., 2009; Liu et al., 2009).
Two nuclear localization signals (NLS) were found in DR5, caus-
ing co-localization with importin 1 and transport to the nucleus
(Kojima et al., 2011). Nuclear localization of DR5 has recently been
implicated in the processing of micro-RNAs (miRNA), such as let-7,
involved in tumor cell differentiation and reveals a possible nuclear
function of the death receptors (Haselmann et al., 2014). The co-
localization of DR5 with microprocessor components reveals a
possible regulatory role over tumor progression and differentia-
tion. The faulty trafﬁcking of DRs to the plasma membrane requires
further examination to determine how to correct this malfunction
for restoration of DR surface expression.
Internalization of DRs. DR surface deﬁciency is caused by vari-
ous internalization mechanisms, such as rapid clathrin-dependent
endocytosis (CDE) (Austin et al., 2006; Chen et al., 2012; Zhang
et al., 2009; Zhang and Zhang, 2008), clathrin-independent endocy-
tosis (CIE) (Kohlhaas et al., 2007), lysosomal degradation (Akazawa
et al., 2009), or autophagosome co-localization (Di et al., 2013).
TRAIL, in contrast to TNF and FasL, does not require internal-
ization to induce an apoptotic signaling cascade (Kohlhaas et al.,
2007), and the endocytosis of DR4 and DR5  after TRAIL-ligation
has drastic implications on apoptotic signaling. Internalization of
the DRs can be accelerated by TRAIL ligation, which was  shown
in hepatocellular carcinoma (HCC), colon adenocarcinoma, cholan-
giocarcinoma and breast cancer cell lines (Akazawa et al., 2009;
Mazurek et al., 2012; Song et al., 2010; Zhang et al., 2009).
Alternatively, TRAIL-receptor endocytosis aids in acquired TRAIL
resistance, upregulating apoptosis inhibitors, preventing contin-
uous caspase activation (Zhang et al., 2009) and inhibiting a
mitochondrial response (Yoshida et al., 2009). Endocytosis of the
TRAIL-DR5 complex in TRAIL- sensitive cells has demonstrated pro-
teolytic cleavage of AP1 and AP2, which are necessary for CDE
(Austin et al., 2006), further inhibiting receptor internalization.
TRAIL-receptor complexes can be targeted for degradation through
ubiquitination by c-Cbl (Kim et al., 2013; Song et al., 2010). Cbl-b is
also implicated in surface DR downregulation through the JNK or
MAPK pathways (Yan et al., 2012).
Prior to sufﬁcient TRAIL-ligation, rapid clathrin- and dynamin-
dependent (Akazawa et al., 2009; Austin et al., 2006; Kohlhaas
et al., 2007; Zhang et al., 2009) endocytosis can occur through faulty
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ileucine sorting signals (Akazawa et al., 2009; Zhang and Zhang,
008). Our previous work has shown that DRs localized to the cyto-
ol in TRAIL-resistant BT474 and AU565 cells and primary tumors
Chen et al., 2012) resulting in surface deﬁciency of DRs. Inhibition
f endocytosis causes a focused localization of DRs, amplifying DISC
ignaling and caspase activation (Akazawa et al., 2009; Zhang et al.,
009). TRAIL is also internalized through CIE (Kohlhaas et al., 2007),
hich may  be regulated by H-Ras in TRAIL resistant cells (Chen
t al., 2014). CIE internalizes membrane proteins such as CD59 and
HCI (Naslavsky et al., 2004). H-Ras localizes on the endosomal
embrane during CIE (Porat-Shliom et al., 2008) and potentially
ids in cell death evasion through mis-localization of DR4 and DR5.
After endocytosis, the DR-TRAIL complex can undergo endo-
omal pH-dependent caspase activated degradation (Austin et al.,
006; Kohlhaas et al., 2007; Zhang et al., 2009), causing the DISC
o dissociate with the death domain of the receptor, or be traf-
cked to the lysosome by Rab 7 for degradation (Akazawa et al.,
009). TRAIL ligation of DR4 or DR5 causes a caspase-8- depend-
nt release of cathepsin B from the lysosome (Werneburg et al.,
007) to initiate cytochrome C mitochondrial release and subse-
uently capsase-3 activation (Werneburg et al., 2007). Lysosomal
egradation prevents receptor recycling back to the plasma mem-
rane for further TRAIL ligation (Song et al., 2010). DR4 or DR5
igation in TRAIL-resistant cells with high FLIP expression causes an
ncrease in autophagic protein production (Han et al., 2008). This
igh basal amount of cytosolic autophagosomes co-localize with
R4 and DR5, aiding in the degradation of DRs (Di et al., 2013). Inhi-
ition of Beclin-1 dependent autophagy increases TRAIL-induced
poptosis (Han et al., 2008). Conversely, blockage of autophagy in
RAIL-sensitive cells reduces sensitivity, indicating a basal level of
utophagy is needed for TRAIL-induced apoptosis (Di et al., 2013).
. Crosstalk between TRAIL apoptosis signaling and
ncogenic Ras pathways
Recent evidence implicates Ras GTPase pathways in the regu-
ation of TRAIL DR expression. The Ras family of small GTPases,
ncluding H-Ras, K-Ras and N-Ras, are downstream of the EGFRs
nd become activated upon ligation of growth factors. Activation
f Ras induces activation of a signaling cascade involving Raf/MAP
inase, PI3K, RalGDS, and other effectors, thereby promoting cell
roliferation, survival, and transformation (Chiariello et al., 2010;
ownward, 2003; Holderﬁeld et al., 2014; Knight and Irving, 2014;
’Hayre et al., 2014; Okada et al., 2014; Pylayeva-Gupta et al., 2011;
oberts and Der, 2007; Suda et al., 2010; Troiani et al., 2013; Vaque
t al., 2013).
Our group has recently analyzed a genome-wide mRNA expres-
ion data set derived from 58 human cancer cells lines and looked
or a correlation between upregulated genes and TRAIL resistance
Chen et al., 2014). Strikingly we identiﬁed H-Ras to be the only
ene whose mRNA overexpression was signiﬁcantly elevated in
RAIL-resistant cells when compared to TRAIL-sensitive cells. By
ontrast, no correlation was found between TRAIL sensitivity and K-
as expression or Ras mutational proﬁles. This unbiased approach
as helped to add some clarity to contradictory reports on the effect
f Ras expression and TRAIL sensitivity. While some work simi-
ar to ours has indicated that TRAIL-resistant cells were sensitized
o TRAIL by inhibiting Ras signaling pathways (Abdulghani et al.,
013; Xu et al., 2013), other reports have suggested the opposite.
n these cases forced ectopic expression of Ras has led to increased
ensitization to TRAIL induced cell death (Drosopoulos et al., 2005;
anzaki et al., 2013; Nesterov et al., 2004; Oh et al., 2012; Sahu et al.,
011; Wang et al., 2005). The discrepancy in results is likely associ-
ted with tumor cell line lineage or the differences in experimental
pproach in terms of Ras inhibition or ectopic expression. Oure Updates 19 (2015) 13–21
previous study however encompasses the screening of a large panel
of cancer cells, hence presumably providing a more accurate rep-
resentation of the true correlation between H-Ras and resistance
to TRAIL. We  validated our mRNA analysis by siRNA knockdown
of Ras in several randomly chosen tumor cell lines. In all tumor
cell lines tested, we observed that isoform-speciﬁc knockdown of
H-Ras and not K-Ras led to increased sensitivity of TRAIL-resistant
cells to TRAIL and agonist anti-DR5 antibody through regulation
of surface expression of DR4 and DR5 (Chen et al., 2014). Interest-
ingly, this H-Ras isoform speciﬁc effect was  also observed in Fas
ligand-mediated apoptosis (Peli et al., 1999).
Notably, it has been shown that lipid raft sequestration of DR4/5
is involved in regulating TRAIL sensitivity (Ouyang et al., 2011;
Peli et al., 1999; Psahoulia et al., 2007; Song et al., 2007; Xu et al.,
2013). In this regard, it is known that H-Ras but not K-Ras can be
anchored to lipid rafts by C-terminal domain palmitoylation, indi-
cating that H-Ras may play a pivotal role in sequestering DR4/5 in
lipid rafts. Moreover, it is the inactive GDP-bound form of H-Ras
that is known to associate to lipid rafts (Prior et al., 2001; Resh,
2006); this may  provide an additional explanation for why  forced
expression of Ras in some cases does not lead to TRAIL resistance.
Lipid raft sequestration can often be the ﬁrst step in autophagic
protein degradation. Indeed, studies have identiﬁed a link between
TRAIL resistance and autophagy (He et al., 2012; Herrero-Martin
et al., 2009; Hou et al., 2010; Mills et al., 2004; Niu et al., 2010;
Zhang and Zhang, 2008), where TRAIL has been shown to induce
autophagy in a number of cancer cell lines, including colon, glioma,
bladder and prostate, and breast carcinoma. Moreover, inhibition
of autophagy by pharmacological inhibitors or by gene silencing
of Beclin-1 or ATG7 (key autophagy regulators) sensitized TRAIL-
resistant tumor cells to TRAIL-induced apoptosis (Han et al., 2008;
Herrero-Martin et al., 2009). Furthermore, crosstalk between Ras
and autophagy has been well documented (Chen et al., 2014; Guo
et al., 2011; Reuter et al., 2000; Schmukler et al., 2014). Ras can
modulate the levels of autophagy in cancer cells, while autophagy
may  affect the progression of Ras-driven tumors. Taken together
the work presented here suggests that H-Ras can serve as a poten-
tial biomarker in the prediction of tumor resistance to DR-targeted
therapies. Moreover, this work warrants further studies of combi-
natorial therapies using TRAIL and inhibitors of EGFR/Ras pathways.
4. Perspectives
A body of evidence reveals that TRAIL death receptors are fre-
quently downregulated in cancer cells, resulting in their absence
from the plasma membrane. The underlying molecular mech-
anisms have just begun to be understood which may involve
defects in protein trafﬁcking, accelerated internalization or other
yet uncharacterized mechanisms. Clearly, lack of surface death
receptors is sufﬁcient to render cancer cells resistant to the tar-
geted therapies, regardless of the status of downstream signaling
components unless some downstream death activating mutation
occurred which is highly unlikely in advanced stages of metastatic
cancers. Therefore, these data provide a rational for a combination
therapy in restoring cell surface expression of death receptors to
achieve an enhanced clinical efﬁcacy for TRAIL receptor-targeted
therapies.
Surface expression of DR4 and DR5 could be evaluated as a
predictive biomarker for identifying patient subpopulations with
tumors that are responsive or resistant to death receptor targeted
agents. The ability to enrich patients for clinical trials has the
potential to increase the success of the relevant drug development.
However, it is not technically feasible to distinguish membrane
bound receptors from cytosolic fractions using the commonly
used immunohistochemistry approaches at the clinical settings.
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dditional studies are warranted to identify intracellular molecules
e.g. H-Ras expression) that control DR4 and DR5 surface expres-
ion. If available, such molecules could facilitate the development
f companion diagnostic tests in the relevant drug development
rograms. Second, the high frequency of DR4/DR5 deﬁciency on
he surface of cancer cells provides a rational for the selection of
ombinational drugs with rhTRAIL and agonistic antibodies. The
ngoing clinical studies currently test various therapeutic combi-
ation strategies (Table 1). As described above, it is desirable to use
rugs that can upregulate the expression of DR4 and DR5 on the
lasma membrane of cancer cells. A proof-of-concept will need to
e established using appropriate in vitro and in vivo models, fol-
owed by examination in relevant clinical studies. Although we  do
ot yet have the knowledge base to successfully overcome can-
er resistance to DR-targeted therapies, our ﬁndings on the DR
ell surface deﬁciency allow us to be optimistic that the delivery
f effective combinational cancer therapeutics will eventually be
ossible.
eferences
bdulghani, J., Allen, J.E., Dicker, D.T., Liu, Y.Y., Goldenberg, D., Smith, C.D.,
Humphreys, R., El-Deiry, W.S., 2013. Sorafenib sensitizes solid tumors to
Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-
Mcl1 axis. PLOS ONE 8, e75414.
dar, Y., Stark, M.,  Bram, E.E., Nowak-Sliwinska, P., van den Bergh, H.,
Szewczyk, G., Sarna, T., Skladanowski, A., Grifﬁoen, A.W., Assaraf, Y.G., 2012.
Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological
Trojan horse approach to eradicate multidrug-resistant cancers. Cell Death Dis.
3,  e293.
hmad, N., Gabius, H.J., Andre, S., Kaltner, H., Sabesan, S., Roy, R., Liu, B., Macaluso, F.,
Brewer, C.F., 2004. Galectin-3 precipitates as a pentamer with synthetic multi-
valent carbohydrates and forms heterogeneous cross-linked complexes. J. Biol.
Chem. 279, 10841–10847.
kazawa, Y., Mott, J.L., Bronk, S.F., Werneburg, N.W., Kahraman, A., Guicciardi, M.E.,
Meng, X.W., Kohno, S., Shah, V.H., Kaufmann, S.H., McNiven, M.A., Gores, G.J.,
2009. Death receptor 5 internalization is required for lysosomal permeabiliza-
tion by TRAIL in malignant liver cell lines. Gastroenterology 136, 2365–2376.
ustin, C.D., Lawrence, D.A., Peden, A.A., Varfolomeev, E.E., Totpal, K., De Maziere,
A.M., Klumperman, J., Arnott, D., Pham, V., Scheller, R.H., Ashkenazi, A., 2006.
Death-receptor activation halts clathrin-dependent endocytosis. Proc. Natl.
Acad. Sci. U.S.A. 103, 10283–10288.
za-Blanc, P., Cooper, C.L., Wagner, K., Batalov, S., Deveraux, Q.L., Cooke, M.P., 2003.
Identiﬁcation of modulators of TRAIL-induced apoptosis via RNAi-based pheno-
typic screening. Mol. Cell 12, 627–637.
aritaki, S., Huerta-Yepez, S., Sakai, T., Spandidos, D.A., Bonavida, B., 2007a.
Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-
regulation of DR5 and inhibition of Yin Yang 1. Mol. Cancer Ther. 6, 1387–1399.
aritaki, S., Katsman, A., Chatterjee, D., Yeung, K.C., Spandidos, D.A., Bonavida, B.,
2007b. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the
metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and
death receptor 5 up-regulation. J. Immunol. 179, 5441–5453.
aritaki, S., Suzuki, E., Umezawa, K., Spandidos, D.A., Berenson, J., Daniels, T.R.,
Penichet, M.L., Jazirehi, A.R., Palladino, M., Bonavida, B., 2008. Inhibition of Yin
Yang 1-dependent repressor activity of DR5 transcription and expression by
the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced
apoptosis in cancer cells. J. Immunol. 180, 6199–6210.
astro, A.C., Terziyska, N., Grunert, M.,  Gundisch, S., Graubner, U., Quintanilla-
Martinez, L., Jeremias, I., 2012. Leukemia-initiating cells of patient-derived
acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. Blood 119,
4224–4227.
hen, J.J., Bozza, W.P., Di, X., Zhang, Y., Hallett, W.,  Zhang, B., 2014. H-Ras regulation
of  TRAIL death receptor mediated apoptosis. Oncotarget 5, 5125–5137.
hen, J.J., Shen, H.C., Rivera Rosado, L.A., Zhang, Y., Di, X., Zhang, B., 2012. Mislo-
calization of death receptors correlates with cellular resistance to their cognate
ligands in human breast cancer cells. Oncotarget 3, 833–842.
hen, Q., Ganapathy, S., Singh, K.P., Shankar, S., Srivastava, R.K., 2010. Resveratrol
induces growth arrest and apoptosis through activation of FOXO transcription
factors in prostate cancer cells. PLoS ONE 5, e15288.
hen, X., Kandasamy, K., Srivastava, R.K., 2003. Differential roles of RelA (p65) and c-
Rel  subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-
inducing ligand signaling. Cancer Res. 63, 1059–1066.
hiariello, M.,  Vaque, J.P., Crespo, P., Gutkind, J.S., 2010. Activation of Ras and Rho
GTPases and MAP  Kinases by G-protein-coupled receptors. Methods Mol. Biol.
661, 137–150.
hoi, Y.H., Yu, A.M., 2014. ABC transporters in multidrug resistance and pharma-
cokinetics, and strategies for drug development. Curr. Pharm. Des. 20, 793–807.
rowder, R.N., El-Deiry, W.S., 2012. Caspase-8 regulation of TRAIL-mediated cell
death. Exp. Oncol. 34, 160–164.e Updates 19 (2015) 13–21 19
Daniel, D., Wilson, N.S., 2008. Tumor necrosis factor: renaissance as a cancer thera-
peutic? Curr. Cancer Drug Targets 8, 124–131.
de Wilt, L.H., Jansen, G., Assaraf, Y.G., van, M.J., Cloos, J., Schimmer, A.D., Chan, E.T.,
Kirk, C.J., Peters, G.J., Kruyt, F.A., 2012. Proteasome-based mechanisms of intrin-
sic and acquired bortezomib resistance in non-small cell lung cancer. Biochem.
Pharmacol. 83, 207–217.
Di, X., Zhang, G., Zhang, Y., Takeda, K., Rivera Rosado, L.A., Zhang, B., 2013. Accumula-
tion of autophagosomes in breast cancer cells induces TRAIL resistance through
downregulation of surface expression of death receptors 4 and 5. Oncotarget 4,
1349–1364.
Dimberg, L.Y., Anderson, C.K., Camidge, R., Behbakht, K., Thorburn, A., Ford, H.L.,
2013. On the TRAIL to successful cancer therapy? Predicting and counteracting
resistance against TRAIL-based therapeutics. Oncogene 32, 1341–1350.
Downward, J., 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev.
Cancer 3, 11–22.
Drosopoulos, K.G., Roberts, M.L., Cermak, L., Sasazuki, T., Shirasawa, S., Andera, L.,
Pintzas, A., 2005. Transformation by oncogenic RAS sensitizes human colon cells
to  TRAIL-induced apoptosis by up-regulating death receptor 4 and death recep-
tor  5 through a MEK-dependent pathway. J. Biol. Chem. 280, 22856–22867.
Eggert, A., Grotzer, M.A., Zuzak, T.J., Wiewrodt, B.R., Ho, R., Ikegaki, N., Brodeur, G.M.,
2001. Resistance to tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of
caspase-8 expression. Cancer Res. 61, 1314–1319.
Fall, D.J., Stessman, H., Patel, S.S., Sachs, Z., Van Ness, B.G., Baughn, L.B., Linden, M.A.,
2014. Utilization of translational bioinformatics to identify novel biomarkers of
bortezomib resistance in multiple myeloma. J. Cancer 5, 720–727.
Fulda, S., 2015. Targeting extrinsic apoptosis in cancer: challenges and opportunities.
Semin. Cell Dev. Biol., http://dx.doi.org/10.1016/j.semcdb.2015.01.006.
Fulda, S., Kufer, M.U., Meyer, E., van, V.F., Dockhorn-Dworniczak, B., Debatin,
K.M., 2001. Sensitization for death receptor- or drug-induced apoptosis by re-
expression of caspase-8 through demethylation or gene transfer. Oncogene 20,
5865–5877.
Ganapathy, S., Chen, Q., Singh, K.P., Shankar, S., Srivastava, R.K., 2010. Resveratrol
enhances antitumor activity of TRAIL in prostate cancer xenografts through
activation of FOXO transcription factor. PLoS ONE 5, e15627.
Goler-Baron, V., Assaraf, Y.G., 2012. Overcoming multidrug resistance via pho-
todestruction of ABCG2-rich extracellular vesicles sequestering photosensitive
chemotherapeutics. PLoS ONE 7, e35487.
Guan, B., Yue, P., Clayman, G.L., Sun, S.Y., 2001. Evidence that the death receptor DR4
is  a DNA damage-inducible, p53-regulated gene. J. Cell Physiol. 188, 98–105.
Guan, B., Yue, P., Lotan, R., Sun, S.Y., 2002. Evidence that the human death receptor
4  is regulated by activator protein 1. Oncogene 21, 3121–3129.
Guo, J.Y., Chen, H.Y., Mathew, R., Fan, J., Strohecker, A.M., Karsli-Uzunbas, G.,  Kam-
phorst, J.J., Chen, G., Lemons, J.M., Karantza, V., Coller, H.A., Dipaola, R.S., Gelinas,
C.,  Rabinowitz, J.D., White, E., 2011. Activated Ras requires autophagy to main-
tain  oxidative metabolism and tumorigenesis. Genes Dev. 25, 460–470.
Han, J., Hou, W.,  Goldstein, L.A., Lu, C., Stolz, D.B., Yin, X.M., Rabinowich, H., 2008.
Involvement of protective autophagy in TRAIL resistance of apoptosis-defective
tumor cells. J. Biol. Chem. 283, 19665–19677.
Haselmann, V., Kurz, A., Bertsch, U., Hubner, S., Olempska-Muller, M.,  Fritsch, J.,
Hasler, R., Pickl, A., Fritsche, H., Annewanter, F., Engler, C., Fleig, B., Bernt, A.,
Roder, C., Schmidt, H., Gelhaus, C., Hauser, C., Egberts, J.H., Heneweer, C., Rohde,
A.M., Boger, C., Knippschild, U., Rocken, C., Adam, D., Walczak, H., Schutze, S.,
Janssen, O., Wulczyn, F.G., Wajant, H., Kalthoff, H., Trauzold, A., 2014. Nuclear
death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation
of  pancreatic and other tumor cells. Gastroenterology 146, 278–290.
He, W.,  Wang, Q., Xu, J., Xu, X., Padilla, M.T., Ren, G., Gou, X., Lin, Y., 2012. Attenu-
ation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway
involving T. Autophagy 8, 1811–1821.
Held, J., Schulze-Osthoff, K., 2001. Potential and caveats of TRAIL in cancer therapy.
Drug Resist. Update 4, 243–252.
Herbst, R.S., Eckhardt, S.G., Kurzrock, R., Ebbinghaus, S., O’Dwyer, P.J., Gordon, M.S.,
Novotny, W.,  Goldwasser, M.A., Tohnya, T.M., Lum, B.L., Ashkenazi, A., Jubb, A.M.,
Mendelson, D.S., 2010. Phase I dose-escalation study of recombinant human
Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced
cancer. J. Clin. Oncol. 28, 2839–2846.
Herrero-Martin, G., Hoyer-Hansen, M., Garcia-Garcia, C., Fumarola, C., Farkas, T.,
Lopez-Rivas, A., Jaattela, M.,  2009. TAK1 activates AMPK-dependent cytopro-
tective autophagy in TRAIL-treated epithelial cells. EMBO J. 28, 677–685.
Hinz, S., Trauzold, A., Boenicke, L., Sandberg, C., Beckmann, S., Bayer, E., Walczak, H.,
Kalthoff, H., Ungefroren, H., 2000. Bcl-XL protects pancreatic adenocarcinoma
cells against. Oncogene 19, 5477–5486.
Holderﬁeld, M., Nagel, T.E., Stuart, D.D., 2014. Mechanism and consequences
of  RAF kinase activation by small-molecule inhibitors. Br. J. Cancer 111,
640–645.
Hou, W.,  Han, J., Lu, C., Goldstein, L.A., Rabinowich, H., 2010. Autophagic degradation
of  active caspase-8: a crosstalk mechanism between autophagy and apoptosis.
Autophagy 6, 891–900.
Jin, H.O., Lee, Y.H., Park, J.A., Kim, J.H., Hong, S.E., Kim, H.A., Kim, E.K., Noh, W.C., Kim,
B.H.,  Ye, S.K., Chang, Y.H., Hong, S.I., Hong, Y.J., Park, I.C., Lee, J.K., 2014. Blockage of
Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition. Biochem.
Biophys. Res. Commun. 444, 502–508.
Jin, Z., McDonald III, E.R., Dicker, D.T., El-Deiry, W.S., 2004. Deﬁcient tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the
cell surface in human colon cancer cells selected for resistance to TRAIL-induced
apoptosis. J. Biol. Chem. 279, 35829–35839.
2 istanc
K
K
K
K
K
K
K
K
K
L
L
L
L
M
M
M
M
M
M
N
N
N
N
N0 J.D. Twomey et al. / Drug Res
anzaki, H., Ohtaki, A., Merchant, F.K., Greene, M.I., Murali, R., 2013. Mutations in
K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell
death in pancreatic ductal adenocarcinoma cells. Exp. Mol. Pathol. 94, 372–379.
eane, M.M., Ettenberg, S.A., Nau, M.M.,  Russell, E.K., Lipkowitz, S., 1999. Chemother-
apy  augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59,
734–741.
im, S.Y., Kim, J.H., Song, J.J., 2013. c-Cbl shRNA-expressing adenovirus sensitizes
TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.
Cancer Gene Ther. 20, 82–87.
ischkel, F.C., Lawrence, D.A., Chuntharapai, A., Schow, P., Kim, K.J., Ashkenazi, A.,
2000. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8
to  death receptors 4 and 5. Immunity 12, 611–620.
ischkel, F.C., Lawrence, D.A., Tinel, A., LeBlanc, H., Virmani, A., Schow, P., Gazdar, A.,
Blenis, J., Arnott, D., Ashkenazi, A., 2001. Death receptor recruitment of endoge-
nous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol.
Chem. 276, 46639–46646.
night, T., Irving, J.A., 2014. Ras/Raf/MEK/ERK Pathway Activation in Childhood
Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. Front. Oncol. 4,
160.
ohlhaas, S.L., Craxton, A., Sun, X.M., Pinkoski, M.J., Cohen, G.M., 2007. Receptor-
mediated endocytosis is not required for tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem. 282,
12831–12841.
ojima, Y., Nakayama, M.,  Nishina, T., Nakano, H., Koyanagi, M.,  Takeda, K., Oku-
mura, K., Yagita, H., 2011. Importin beta1 protein-mediated nuclear localization
of  death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells. J.
Biol.  Chem. 286, 43383–43393.
urita, S., Mott, J.L., Almada, L.L., Bronk, S.F., Werneburg, N.W., Sun, S.Y., Roberts,
L.R., Fernandez-Zapico, M.E., Gores, G.J., 2010. GLI3-dependent repression of
DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. Oncogene 29,
4848–4858.
awrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan,
K.,  Totpal, K., Deforge, L., Schow, P., Hooley, J., Sherwood, S., Pai, R., Leung,
S.,  Khan, L., Gliniak, B., Bussiere, J., Smith, C.A., Strom, S.S., Kelley, S., Fox, J.A.,
Thomas, D., Ashkenazi, A., 2001. Differential hepatocyte toxicity of recombinant
Apo2L/TRAIL versions. Nat. Med. 7, 383–385.
eithner, K., Stacher, E., Wurm, R., Ploner, F., Quehenberger, F., Wohlkoenig, C., Balint,
Z., Polachova, J., Olschewski, A., Samonigg, H., Popper, H.H., Olschewski, H., 2009.
Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with
non-small cell lung cancer treated with chemotherapy. Lung Cancer 65, 98–104.
eong, S., Cohen, R.B., Gustafson, D.L., Langer, C.J., Camidge, D.R., Padavic, K., Gore,
L.,  Smith, M.,  Chow, L.Q., von, M.M.,  O’Bryant, C., Hariharan, S., Diab, S., Fox, N.L.,
Miceli, R., Eckhardt, S.G., 2009. Mapatumumab, an antibody targeting TRAIL-R1,
in  combination with paclitaxel and carboplatin in patients with advanced solid
malignancies: results of a phase I and pharmacokinetic study. J. Clin. Oncol. 27,
4413–4421.
iu, G.C., Zhang, J., Liu, S.G., Gao, R., Long, Z.F., Tao, K., Ma,  Y.F., 2009. Detachment
of esophageal carcinoma cells from extracellular matrix causes relocalization of
death receptor 5 and apoptosis. World J. Gastroenterol. 15, 836–844.
ahalingam, D., Mita, A., Sankhala, K., Swords, R., Kelly, K., Giles, F., Mita, M.M., 2009.
Targeting sarcomas: novel biological agents and future perspectives. Curr. Drug
Targets 10, 937–949.
azurek, N., Byrd, J.C., Sun, Y., Haﬂey, M.,  Ramirez, K., Burks, J., Bresalier, R.S., 2012.
Cell-surface galectin-3 confers resistance to TRAIL by impeding trafﬁcking of
death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ. 19,
523–533.
ellier, G., Pervaiz, S., 2012. The three Rs along the TRAIL: resistance, re-sensitization
and reactive oxygen species (ROS). Free Radic. Res. 46, 996–1003.
endoza, F.J., Ishdorj, G., Hu, X., Gibson, S.B., 2008. Death receptor-4 (DR4) expres-
sion is regulated by transcription factor NF-kappaB in response to etoposide
treatment. Apoptosis 13, 756–770.
ills, K.R., Reginato, M.,  Debnath, J., Queenan, B., Brugge, J.S., 2004. Tumor necro-
sis factor-related apoptosis-inducing ligand (TRAIL) is required for induction
of  autophagy during lumen formation in vitro. Proc. Natl. Acad. Sci. U.S.A. 101,
3438–3443.
oon, D.O., Kang, C.H., Kang, S.H., Choi, Y.H., Hyun, J.W., Chang, W.Y., Kang, H.K.,
Koh, Y.S., Maeng, Y.H., Kim, Y.R., Kim, G.Y., 2012. Capsaicin sensitizes TRAIL-
induced apoptosis through Sp1-mediated DR5 up-regulation: involvement of
Ca(2+) inﬂux. Toxicol. Appl. Pharmacol. 259, 87–95.
aslavsky, N., Weigert, R., Donaldson, J.G., 2004. Characterization of a nonclathrin
endocytic pathway: membrane cargo and lipid requirements. Mol. Biol. Cell 15,
3542–3552.
esterov, A., Nikrad, M.,  Johnson, T., Kraft, A.S., 2004. Oncogenic Ras sensitizes
normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing
ligand-induced apoptosis. Cancer Res. 64, 3922–3927.
iewerth, D., Jansen, G., Riethoff, L.F., van, M.J., Kale, A.J., Moore, B.S., Assaraf, Y.G.,
Anderl, J.L., Zweegman, S., Kaspers, G.J., Cloos, J., 2014a. Antileukemic activity
and mechanism of drug resistance to the marine Salinispora tropica proteasome
inhibitor salinosporamide A (Marizomib). Mol. Pharmacol. 86, 12–19.
iewerth, D., Kaspers, G.J., Assaraf, Y.G., van, M.J., Kirk, C.J., Anderl, J., Blank, J.L., van de
Ven, P.M., Zweegman, S., Jansen, G., Cloos, J., 2014b. Interferon-gamma-induced
upregulation of immunoproteasome subunit assembly overcomes bortezomib
resistance in human hematological cell lines. J. Hematol. Oncol. 7, 7.
iewerth, D., van, M.J., Jansen, G., Assaraf, Y.G., Hendrickx, T.C., Kirk, C.J., Anderl,
J.L.,  Zweegman, S., Kaspers, G.J., Cloos, J., 2014c. Anti-leukemic activity ande Updates 19 (2015) 13–21
mechanisms underlying resistance to the novel immunoproteasome inhibitor
PR-924. Biochem. Pharmacol. 89, 43–51.
Niu, T.K., Cheng, Y., Ren, X., Yang, J.M., 2010. Interaction of Beclin 1 with survivin
regulates sensitivity of human glioma cells to TRAIL-induced apoptosis. FEBS
Lett. 584, 3519–3524.
O’Hayre, M.,  Degese, M.S., Gutkind, J.S., 2014. Novel insights into G protein and
G  protein-coupled receptor signaling in cancer. Curr. Opin. Cell Biol. 27,
126–135.
Oh, Y.T., Liu, X., Yue, P., Kang, S., Chen, J., Taunton, J., Khuri, F.R., Sun, S.Y., 2010.
ERK/ribosomal S6 kinase (RSK) signaling positively regulates death recep-
tor  5 expression through co-activation of CHOP and Elk1. J. Biol. Chem. 285,
41310–41319.
Oh, Y.T., Yue, P., Zhou, W.,  Balko, J.M., Black, E.P., Owonikoko, T.K., Khuri, F.R., Sun,
S.Y., 2012. Oncogenic Ras and B-Raf proteins positively regulate death receptor
5  expression through co-activation of ERK and JNK signaling. J. Biol. Chem. 287,
257–267.
Oikonomou, E., Kothonidis, K., Taouﬁk, E., Probert, E., Zografos, G., Nasioulas, G.,
Andera, L., Pintzas, A., 2007. Newly established tumourigenic primary human
colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in
vivo. Br. J. Cancer 97, 73–84.
Okada, Y., Miyamoto, H., Goji, T., Takayama, T., 2014. Biomarkers for predicting the
efﬁcacy of anti-epidermal growth factor receptor antibody in the treatment of
colorectal cancer. Digestion 89, 18–23.
Orlowski, R.Z., 2013. Novel agents for multiple myeloma to overcome resistance in
phase III clinical trials. Semin. Oncol. 40, 634–651.
Ouyang, W.,  Yang, C., Liu, Y., Xiong, J., Zhang, J., Zhong, Y., Zhang, G., Zhou, F., Zhou,
Y.,  Xie, C., 2011. Redistribution of DR4 and DR5 in lipid rafts accounts for the
sensitivity to TRAIL in NSCLC cells. Int. J. Oncol. 39, 1577–1586.
Ozoren, N., El-Deiry, W.S., 2003. Cell surface death receptor signaling in normal and
cancer cells. Semin. Cancer Biol. 13, 135–147.
Partridge, E.A., Le, R.C., Di Guglielmo, G.M., Pawling, J., Cheung, P., Granovsky, M.,
Nabi, I.R., Wrana, J.L., Dennis, J.W., 2004. Regulation of cytokine receptors by
Golgi N-glycan processing and endocytosis. Science 306, 120–124.
Peli, J., Schroter, M.,  Rudaz, C., Hahne, M.,  Meyer, C., Reichmann, E., Tschopp, J., 1999.
Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the
expression of Fas. EMBO J. 18, 1824–1831.
Porat-Shliom, N., Kloog, Y., Donaldson, J.G., 2008. A unique platform for H-Ras
signaling involving clathrin-independent endocytosis. Mol. Biol. Cell 19,
765–775.
Prior, I.A., Harding, A., Yan, J., Sluimer, J., Parton, R.G., Hancock, J.F., 2001. GTP-
dependent segregation of H-ras from lipid rafts is required for biological activity.
Nat. Cell Biol. 3, 368–375.
Psahoulia, F.H., Drosopoulos, K.G., Doubravska, L., Andera, L., Pintzas, A., 2007.
Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by induc-
ing the accumulation of death receptors in lipid rafts. Mol. Cancer Ther. 6,
2591–2599.
Pylayeva-Gupta, Y., Grabocka, E., Bar-Sagi, D., 2011. RAS oncogenes: weaving a
tumorigenic web. Nat. Rev. Cancer 11, 761–774.
Ravi, R., Bedi, G.C., Engstrom, L.W., Zeng, Q., Mookerjee, B., Gelinas, C., Fuchs, E.J., Bedi,
A.,  2001. Regulation of death receptor expression and TRAIL/Apo2L-induced
apoptosis by NF-kappaB. Nat. Cell Biol. 3, 409–416.
Resh, M.D., 2006. Palmitoylation of ligands, receptors, and intracellular signaling
molecules. Sci. STKE 2006, re14.
Reuter, C.W., Morgan, M.A., Bergmann, L., 2000. Targeting the Ras signaling pathway:
a  rational, mechanism-based treatment for hematologic malignancies? Blood
96,  1655–1669.
Roberts, N.J., Zhou, S., Diaz Jr., L.A., Holdhoff, M.,  2011. Systemic use of tumor necrosis
factor alpha as an anticancer agent. Oncotarget 2, 739–751.
Roberts, P.J., Der, C.J., 2007. Targeting the Raf-MEK-ERK mitogen-activated protein
kinase cascade for the treatment of cancer. Oncogene 26, 3291–3310.
Sahu, R.P., Batra, S., Kandala, P.K., Brown, T.L., Srivastava, S.K., 2011. The role of K-ras
gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell
lines. Cancer Chemother. Pharmacol. 67, 481–487.
Schmukler, E., Kloog, Y., Pinkas-Kramarski, R., 2014. Ras and autophagy in cancer
development and therapy. Oncotarget 5, 577–586.
Shankar, S., Srivastava, R.K., 2004. Enhancement of therapeutic potential of TRAIL
by cancer chemotherapy and irradiation: mechanisms and clinical implications.
Drug Resist. Update 7, 139–156.
Shapira, A., Livney, Y.D., Broxterman, H.J., Assaraf, Y.G., 2011. Nanomedicine for tar-
geted cancer therapy: towards the overcoming of drug resistance. Drug Resist.
Update 14, 150–163.
Sheikh, M.S., Burns, T.F., Huang, Y., Wu,  G.S., Amundson, S., Brooks, K.S., Fornace Jr.,
A.J., El-Deiry, W.S., 1998. p53-dependent and -independent regulation of the
death receptor KILLER/DR5 gene expression in response to genotoxic stress and
tumor necrosis factor alpha. Cancer Res. 58, 1593–1598.
Shetty, S., Gladden, J.B., Henson, E.S., Hu, X., Villanueva, J., Haney, N., Gibson,
S.B., 2002. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-
regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial
derived cell lines. Apoptosis 7, 413–420.
Shetty, S., Graham, B.A., Brown, J.G., Hu, X., Vegh-Yarema, N., Harding, G., Paul,
J.T.,  Gibson, S.B., 2005. Transcription factor NF-kappaB differentially regulates
death receptor 5 expression involving histone deacetylase 1. Mol. Cell Biol. 25,
5404–5416.
Shoeb, M., Ramana, K.V., Srivastava, S.K., 2013. Aldose reductase inhibition enhances
TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-
dependent upregulation of death receptors. Free Radic. Biol. Med. 63, 280–290.
istanc
S
S
S
S
S
S
S
S
S
S
T
T
T
v
v
V
W
WJ.D. Twomey et al. / Drug Res
iegelin, M.D., 2012. Utilization of the cellular stress response to sensitize cancer
cells to TRAIL-mediated apoptosis. Expert Opin. Ther. Targets 16, 801–817.
imova, S., Klima, M.,  Cermak, L., Sourkova, V., Andera, L., 2008. Arf and Rho GAP
adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the
plasma membrane. Apoptosis 13, 423–436.
ingh, T.R., Shankar, S., Chen, X., Asim, M.,  Srivastava, R.K., 2003. Synergistic
interactions of chemotherapeutic drugs and tumor necrosis factor-related
apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast
carcinoma in vivo. Cancer Res. 63, 5390–5400.
ingh, T.R., Shankar, S., Srivastava, R.K., 2005. HDAC inhibitors enhance the
apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24,
4609–4623.
now, A.L., Vaysberg, M., Krams, S.M., Martinez, O.M., 2006. EBV B lymphoma cell
lines  from patients with post-transplant lymphoproliferative disease are resis-
tant to TRAIL-induced apoptosis. Am.  J. Transpl. 6, 976–985.
ong, J.H., Tse, M.C., Bellail, A., Phuphanich, S., Khuri, F., Kneteman, N.M., Hao, C.,
2007. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-
inducing ligand induced apoptotic and nonapoptotic signals in non small cell
lung carcinoma cells. Cancer Res. 67, 6946–6955.
ong, J.J., Szczepanski, M.J., Kim, S.Y., Kim, J.H., An, J.Y., Kwon, Y.T., Alcala Jr., M.A.,
Bartlett, D.L., Lee, Y.J., 2010. c-Cbl-mediated degradation of TRAIL receptors is
responsible for the development of the early phase of TRAIL resistance. Cell.
Signal. 22, 553–563.
oria, J.C., Mark, Z., Zatloukal, P., Szima, B., Albert, I., Juhasz, E., Pujol, J.L., Kozielski,
J.,  Baker, N., Smethurst, D., Hei, Y.J., Ashkenazi, A., Stern, H., Amler, L., Pan, Y.,
Blackhall, F., 2011. Randomized phase II study of dulanermin in combination
with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung
cancer. J. Clin. Oncol. 29, 4442–4451.
tegehuis, J.H., de Wilt, L.H., de Vries, E.G., Groen, H.J., de, J.S., Kruyt, F.A., 2010. TRAIL
receptor targeting therapies for non-small cell lung cancer: current status and
perspectives. Drug Resist. Update 13, 2–15.
uda, K., Tomizawa, K., Mitsudomi, T., 2010. Biological and clinical signiﬁcance of
KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR
mutation. Cancer Metastasis Rev. 29, 49–60.
akimoto, R., El-Deiry, W.S., 2000. Wild-type p53 transactivates the KILLER/DR5
gene through an intronic sequence-speciﬁc DNA-binding site. Oncogene 19,
1735–1743.
horburn, A., Behbakht, K., Ford, H., 2008. TRAIL receptor-targeted therapeutics:
resistance mechanisms and strategies to avoid them. Drug Resist. Update 11,
17–24.
roiani, T., Zappavigna, S., Martinelli, E., Addeo, S.R., Stiuso, P., Ciardiello, F., Caraglia,
M., 2013. Optimizing treatment of metastatic colorectal cancer patients with
anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.
Expert Opin. Biol. Ther. 13, 241–255.
an Geelen, C.M., de Vries, E.G., de, J.S., 2004. Lessons from TRAIL-resistance mech-
anisms in colorectal cancer cells: paving the road to patient-tailored therapy.
Drug Resist. Update 7, 345–358.
an Roosmalen, I.A., Quax, W.J., Kruyt, F.A., 2014. Two  death-inducing human
TRAIL receptors to target in cancer: similar or distinct regulation and function?
Biochem. Pharmacol. 91, 447–456.
aque, J.P., Dorsam, R.T., Feng, X., Iglesias-Bartolome, R., Forsthoefel, D.J., Chen,
Q., Debant, A., Seeger, M.A., Ksander, B.R., Teramoto, H., Gutkind, J.S., 2013. A
genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry trans-
ducing mitogenic signals initiated by G protein-coupled receptors. Mol. Cell 49,
94–108.
agner, K.W., Punnoose, E.A., Januario, T., Lawrence, D.A., Pitti, R.M., Lancaster, K.,
Lee,  D., von, G.M., Yee, S.F., Totpal, K., Huw, L., Katta, V., Cavet, G., Hymowitz,
S.G., Amler, L., Ashkenazi, A., 2007. Death-receptor O-glycosylation controls
tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13,
1070–1077.
alczak, H., Miller, R.E., Ariail, K., Gliniak, B., Grifﬁth, T.S., Kubin, M.,  Chin, W.,  Jones,
J.,  Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R.G., Rauch, C.T., Schuh,e Updates 19 (2015) 13–21 21
J.C., Lynch, D.H., 1999. Tumoricidal activity of tumor necrosis factor-related
apoptosis-inducing ligand in vivo. Nat. Med. 5, 157–163.
Wang, Y., Quon, K.C., Knee, D.A., Nesterov, A., Kraft, A.S., 2005. RAS, MYC, and sensi-
tivity to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced
apoptosis. Cancer Res. 65, 1615–1616.
Werneburg, N.W., Guicciardi, M.E., Bronk, S.F., Kaufmann, S.H., Gores, G.J., 2007.
Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal
pathway of apoptosis that is regulated by Bcl-2 proteins. J. Biol. Chem. 282,
28960–28970.
Wu,  G.S., Burns, T.F., McDonald III, E.R., Jiang, W.,  Meng, R., Krantz, I.D., Kao, G., Gan,
D.D., Zhou, J.Y., Muschel, R., Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu,
G.,  El-Deiry, W.S., 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated
death receptor gene. Nat. Genet. 17, 141–143.
Wu,  Y.H., Yang, C.Y., Chien, W.L., Lin, K.I., Lai, M.Z., 2012. Removal of syndecan-
1  promotes TRAIL-induced apoptosis in myeloma cells. J. Immunol. 188,
2914–2921.
Xu, L., Hu, X., Qu, X., Hou, K., Zheng, H., Liu, Y., 2013. Cetuximab enhances TRAIL-
induced gastric cancer cell apoptosis by promoting DISC formation in lipid rafts.
Biochem. Biophys. Res. Commun. 439, 285–290.
Yamaguchi, H., Wang, H.G., 2004. CHOP is involved in endoplasmic reticulum stress-
induced apoptosis by enhancing DR5 expression in human carcinoma cells. J.
Biol. Chem. 279, 45495–45502.
Yan, S., Qu, X., Xu, C., Zhu, Z., Zhang, L., Xu, L., Song, N., Teng, Y., Liu, Y., 2012.
Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and
sensitization of TRAIL-induced apoptosis in breast cancer cells. J. Cancer Res.
Clin. Oncol. 138, 1279–1289.
Yoshida, T., Maeda, A., Tani, N., Sakai, T., 2001. Promoter structure and transcription
initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett. 507,
381–385.
Yoshida, T., Shiraishi, T., Horinaka, M.,  Wakada, M.,  Sakai, T., 2007. Glycosyl-
ation modulates TRAIL-R1/death receptor 4 protein: different regulations
of  two pro-apoptotic receptors for TRAIL by tunicamycin. Oncol. Rep. 18,
1239–1242.
Yoshida, T., Shiraishi, T., Nakata, S., Horinaka, M.,  Wakada, M.,  Mizutani, Y., Miki,
T.,  Sakai, T., 2005. Proteasome inhibitor MG132 induces death receptor 5
through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 65,
5662–5667.
Yoshida, T., Zhang, Y., Rivera Rosado, L.A., Zhang, B., 2009. Repeated treatment with
subtoxic doses of TRAIL induces resistance to apoptosis through its death recep-
tors  in MDA-MB-231 breast cancer cells. Mol. Cancer Res. 7, 1835–1844.
Zhang, X.D., Franco, A.V., Nguyen, T., Gray, C.P., Hersey, P., 2000. Differential
localization and regulation of death and decoy receptors for TNF-related
apoptosis-inducing ligand (TRAIL) in human melanoma cells. J. Immunol. 164,
3961–3970.
Zhang, Y., Yoshida, T., Zhang, B., 2009. TRAIL induces endocytosis of its death recep-
tors in MDA-MB-231 breast cancer cells. Cancer Biol. Ther. 8, 917–922.
Zhang, Y., Zhang, B., 2008. TRAIL resistance of breast cancer cells is associated
with constitutive endocytosis of death receptors 4 and 5. Mol. Cancer Res. 6,
1861–1871.
Zhao, Y., Kalari, S.K., Usatyuk, P.V., Gorshkova, I., He, D., Watkins, T., Brindley, D.N.,
Sun, C., Bittman, R., Garcia, J.G., Berdyshev, E.V., Natarajan, V., 2007. Intracellular
generation of sphingosine 1-phosphate in human lung endothelial cells: role of
lipid phosphate phosphatase-1 and sphingosine kinase 1. J. Biol. Chem. 282,
14165–14177.
Zhitomirsky, B., Assaraf, Y.G., 2015. Lysosomal sequestration of hydrophobic
weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-
dependent cancer multidrug resistance. Oncotarget 6, 1143–1156.Zou, W.,  Liu, X., Yue, P., Zhou, Z., Sporn, M.B., Lotan, R., Khuri, F.R., Sun, S.Y., 2004. c-Jun
NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes
to  induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-
3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 64,
7570–7578.
